Clinical trial · Observational
Radiofrequency-assisted Liver Resection in Intractable Liver Cancer
The Application of Radiofrequency-assisted Liver Resection in Intractable Liver Cancer
NCT04413526CI-TRIAL-00055131completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this retrospective study, the investigators assessed the application of radiofrequency-assisted liver resection in intractable liver cancer resection, and plan to analysis the different factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiofrequency | Procedure | — | UNRESOLVED |
| TACE | Procedure | — | UNRESOLVED |
| TACE+radiofrequency | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- radiofrequency-assisted liver resection
- description
- radiofrequency-assisted liver resection for intractable liver cancer
- interventionNames
- Procedure: radiofrequency
- label
- TACE(transcatheter arterial chemoembolization)
- description
- temporary TACE for intractable liver cancer
- interventionNames
- Procedure: TACE
- label
- radiofrequency ablation plus TACE
- description
- radiofrequency ablation plus TACE for intractable liver cancer
- interventionNames
- Procedure: TACE+radiofrequency
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Ultrasound-guided fine-needle aspiration pathology or postoperative pathology was confirmed to be liver cancer, no pathological results according to China 's 2017 version of the hepatocarcinoma (HCC) diagnosis and treatment specifications, in line with the standard clinical diagnosis of liver cancer * According to Barcelona Clinic Liver Cancer (BCLC) staging criteria, it is stage C (stage C: single tumour\> 5 cm or more than three tumours, and at least one tumour\> 3 cm, liver function Child-Pugh A or B, with lymph node metastasis or distant metastasis or portal vein or Venous liver trunk is invaded, penance Status (PST) score 1-2 points) Exclusion Criteria: * HCC patients with other malignant tumours * Metastatic liver tumour * Patients with liver abscess * Patients with organ dysfunction
References
Publications (1)
- BACKGROUNDSun Y, Ji S, Ji H, Liu L, Li C. Clinical efficacy analysis of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in primary liver cancer and recurrent liver cancer. J BUON. 2019 Jul-Aug;24(4):1402-1407. PMID 31646783